Skip to main content
Caplight Logo









PRO Therapeutics

PRO Therapeutics

Private
Manchester, New HampshireHealthcare & Life Scienceshttps://pro-thera.com/

Last Round

Seed

Dec 5, 2024

Total Funding Raised

$1.8M

Company Overview

PRO Therapeutics, LLC is a regenerative medicine company that develops and commercializes tissue-engineered grafts for soft tissue repair.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinetissue engineeringrotator cuff repairbiotechmedical devicesoft tissue repairbiofabricationregenerative implantorthopedic surgerymusculoskeletal repairSBIRSTTR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PRO Therapeutics Comparables

Compare PRO Therapeutics with similar companies based on industry and business-model similarity.

PRO Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tetrous
85%
Atreon Orthopedics
82%
Zimmer Biomet
77%

PRO Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 5, 2024
GrantJul 17, 2023

Key People

Founding team and executive leadership

Adam Jakus

Chief Executive Officer

Executive Team

PRO Therapeutics Investors

Notable investors and investment history

PRO Therapeutics investors
InvestorRounds
Innovation PartnershipsSeed
National Institutes of Health (NIH)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Monthly visitors increased 1194% MoM, from 33 to 427.

  • Dec 5, 2024

    Seed round raised with Innovation Partnerships participating.

PRO Therapeutics Filings

Explore SEC and related filing metadata, where available.

PRO Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PRO Therapeutics's valuation, stock price, and market status.

Is PRO Therapeutics a public or private company?

PRO Therapeutics is a private company.

What is the current stock price of PRO Therapeutics?

PRO Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is PRO Therapeutics worth (valuation)?

Valuation information for PRO Therapeutics is not publicly available.

Can I buy PRO Therapeutics stock?

PRO Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PRO Therapeutics's last funding round?

PRO Therapeutics's most recent funding round was Seed on December 5, 2024.

Who are the main investors in PRO Therapeutics?

Key investors in PRO Therapeutics include National Institutes of Health (NIH).

Will PRO Therapeutics IPO soon?

No public IPO plans have been announced for PRO Therapeutics.

How can I track PRO Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PRO Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersManchester, New Hampshire
Employee Range4
Year Founded2023
Last FundingDec 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?